Storytelling Co – Lifestyle
Author:
Tarsus Pharmaceuticals, Inc
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
May 6, 2026
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 29, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 31, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
March 23, 2026